Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,821 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.
Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, Kazami Y, Washizaki A, Masuta Y, Suzuki R, Matsuda K, Komori M, Morey AL, Ishimoto K, Nakata M, Hasunuma T, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Sato N. Akahata W, et al. Among authors: matsuda k. Cell Rep Med. 2023 Aug 15;4(8):101134. doi: 10.1016/j.xcrm.2023.101134. Cell Rep Med. 2023. PMID: 37586325 Free PMC article. Clinical Trial.
saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.
Komori M, Nogimori T, Morey AL, Sekida T, Ishimoto K, Hassett MR, Masuta Y, Ode H, Tamura T, Suzuki R, Alexander J, Kido Y, Matsuda K, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Akahata W. Komori M, et al. Among authors: matsuda k. Nat Commun. 2023 May 19;14(1):2810. doi: 10.1038/s41467-023-38457-x. Nat Commun. 2023. PMID: 37208330 Free PMC article.
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.
Aboshi M, Matsuda K, Kawakami D, Kono K, Kazami Y, Sekida T, Komori M, Morey AL, Suga S, Smith JF, Fukuhara T, Iwatani Y, Yamamoto T, Sato N, Akahata W. Aboshi M, et al. Among authors: matsuda k. iScience. 2024 Jan 22;27(2):108964. doi: 10.1016/j.isci.2024.108964. eCollection 2024 Feb 16. iScience. 2024. PMID: 38352232 Free PMC article.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762-8. Online ahead of print. Lancet. 2024. PMID: 39581202
3,821 results